Divarasib controlled KRAS G12C-positive lung cancer longer than the currently available targeted pills, with fewer side ...

For people with lung or pancreatic cancer driven by changes in the KRAS gene, research presented at the 2026 European Society ...

The investigational KRAS G12C inhibitor prolongs overall survival in previously treated advanced lung cancer vs existing ...

Patients with previously treated advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC) lived significantly longer and ...

At one of the year’s premiere meetings for cancer research, melanoma vaccine data hailed by scientists sparked a share ...

In the Krascedo-1 trial, Roche's KRAS G12C inhibitor divarasib met the company's high expectations, with a head-to-head win ...

Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today pivotal results from the Phase III ...

One of the more impressive data sets at this year’s ESMO came from a Roche study of its drug divarasib, which treats lung ...

The Krascendo 1 study showed improved survival rates of 18 months compared to 12 months with current standard of care ...

Among 85 patients treated with olomorasib plus pembrolizumab without chemotherapy, median progression-free survival and ...

Figure 2: Distribution of mutations in KRAS mutated cases of prostate acinar adenocarcinoma. KRAS is one of the most extensively studied oncogenes in cancer, and the G12C variant has become clinically ...

Divarasib monotherapy demonstrated superior efficacy over first-generation KRAS G12C inhibitors, lowering the risk of disease ...